Shows
The HemOnc PulseThe Data Problem in T-Cell Lymphoma CareIn this episode of TheHemOnc Pulse, Rahul Banerjee, MD, speaks with Francine Foss, MD, professor of medicine and dermatology at Yale School of Medicine, about the evolving landscape of T-cell lymphomas. Dr Foss discusses the unique challenges of studying and treating rare diseases such as cutaneous T-cell lymphoma and explains why real-world data are essential to closing evidence gaps. The conversation highlights the role of collaborative registries in tracking treatment patterns, outcomes, and access to care across community and academic settings. Dr Foss also shares how both clinicians and patients can participate in these efforts to strengthen research, inform...
2026-01-2708 min
OncLive® On AirEmerging CELMoDs Set New Standards for Efficacy and Tolerability in Myeloma: With Rahul Banerjee, MD, FACP
In today’s episode, we had the pleasure of speaking with Rahul Banerjee, MD, FACP, about the ongoing investigation of CELMoDs for multiple myeloma. Dr Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center, as well as an assistant professor in the Division of Hematology and Oncology at the University of Washington in Seattle. In our exclusive interview, Dr Banerjee discussed the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with traditional immunomodulatory drugs (IMiDs) like lenalidomide (Revlimid) and pomalidomide (Pomalyst). He also noted strong pre...
2026-01-1618 minThe HemOnc PulseHolding the Line in AML: Real-World Care Meets Breakthrough TrialsDr. Eunice Wang joins host Rahul Banerjee, MD, for a clinician-focused discussion on AML, treatment complexity, and real-world leukemia management in today’s evolving therapeutic landscape.
2025-12-2009 minThe HemOnc PulseToxicity, Time, and the Patient Experience in Blood CancersDr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.
2025-10-0321 minThe HemOnc PulseEditor's Special Episode: Future Directions in MPN Treatment with Dr. HobbsDr. Hobbs joins the podcast to discuss the latest advances in myeloproliferative neoplasms (MPNs), including ropeginterferon and the VERIFY trial of rusfertide in polycythemia vera. He highlights key efficacy and safety data, unmet needs in essential thrombocythemia and myelofibrosis, and the next wave of clinical trials to watch.
2025-10-0117 minThe HemOnc PulseClinical Advances in Myeloma: A Nordic PerspectiveHost Rahul Banerjee, MD, speaks with Drs. Frederik Schjesvold and Frida Askeland on myeloma trial results, relevance in the IMROZ/CEPHEUS era, and advances in treating elderly, frail patients.
2025-09-1212 minThe HemOnc PulseGrand Rounds in Leukemia: MD Anderson Fellows on AML EndpointsMD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.
2025-09-0709 minThe HemOnc PulseEditor’s Special Episode: Progress and Prospects in CLL ManagementWilliam Wierda, MD, PhD of the University of Texas MD Anderson discusses advances in chronic lymphocytic leukemia care, from targeted therapies and resistance to immune dysfunction and prevention with Blood Cancers Today Managing Editor, Nichole Tucker.
2025-08-2711h 22The HemOnc PulseToday’s Clinical Trials Define the Next Era in MyelomaIn this Editor’s Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding long-term MonumenTAL-1 data with talquetamab, to the promise of emerging trispecific antibodies, Dr. Mian highlights the biggest shifts shaping care today.
2025-08-228h 31The HemOnc Pulse‘The HemOnc Pulse Live:’ Transforming ALL Treatment PathwaysA panel of hematology leaders discusses the latest in ALL and T-cell ALL therapy, including TKI+blina combinations, venetoclax strategies, and the emerging role of CD7 CAR T-cell therapies in reshaping treatment paradigms.
2025-08-157h 22The HemOnc PulseEvolving Approaches in the Management of MDSReview of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.
2025-08-0831 minThe HemOnc Pulse‘The HemOnc Pulse Live!’: AML in TransitionDuring a session at The HemOnc Pulse Live! moderated by Naval Daver, MD, Eunice Wang, MD presents new insights in acute myeloid leukemia care, joined by Aditi Shastri, MBBS, Tapan Kadiya, MD, and Kelly Chien, MD for a rich panel on mutation loss, minimal residual disease, and transplant timing.
2025-08-016h 11The HemOnc PulseFrom Trials to Practice: What's New and What's Next for MyelomaDrs. Gurbakhash Kaur and Danai Dima discuss next-gen CAR T and bispecific therapies for myeloma, including agents for extramedullary disease and GPRC5D targets.
2025-07-2537 minThe HemOnc PulseEditor’s Special Episode: Innovations in B-NHL
In this Editor’s Special of The HemOnc Pulse, Tycel Phillips, MD, joins an editor of Blood Cancers Today to break down the latest research in B-cell non-Hodgkin lymphoma presented at the 2025 ASCO Annual Meeting. The conversation spans follicular lymphoma, CLL, mantle cell lymphoma, and large B-cell lymphoma, covering key insights on BTK/BCL2 inhibitors, bispecifics, CAR T-cell therapy, and more.
2025-07-1822 minThe HemOnc PulseEditor’s Special Episode: Treating CLL Now and in the Future
Hematologist-oncologist Dr. Alexey Danilov shares expert insights on chronic lymphocytic leukemia, highlighting unmet needs in immune management, the challenges of Richter’s transformation, and promising data on BTK degraders for double-refractory patients.
2025-07-149h 14The HemOnc Pulse'The HemOnc Pulse Live': Controversies in Frontline Myeloma
Saad Usmani, MD, MBA leads an in-depth discussion with a panel of leading myeloma experts; Dr. Caitlin Costello, Dr. Binod Dhakal, Dr. Pete Voorhees, and Dr. Shambavi Richard on the evolving landscape of frontline multiple myeloma treatment. The conversation covers the rationale behind quadruplet therapy, the integration of minimal residual disease as a response-adaptive strategy, and shifting perspectives on transplant eligibility and timing. Drawing on recent clinical trial data and personal clinical experience, the panel explores how these advancements are influencing treatment decisions and improving long-term outcomes for patients with newly diagnosed myeloma.
2025-07-0327 minThe HemOnc PulseEditor’s Special Episode: ASCO 2025 Highlights in AML with Dr. Amir FathiIn this Editor’s Special of The HemOnc Pulse, Blood Cancers Today Managing Editor, Nichole Tucker speaks with Amir Fathi, MD, of Massachusetts General Hospital, about key updates in AML from ASCO 2025. The discussion centers on a phase 2 study of an all-oral regimen—decitabine and cedazuridine plus venetoclax—for patients with newly diagnosed AML who are unfit for intensive induction.
Dr. Fathi discusses the potential for these more convenient therapies to shift treatment into the outpatient setting while maintaining effectiveness. He also shares insights on promising triplet regimens incorporating targeted therapies and highlights the need for new strate...
2025-06-2915 minThe HemOnc PulseNavigating Drug Accessibility in Cancer Care
In this episode of The Hem Onc Pulse, Dr. Rahul Banerjee is joined by Dr. Michelle Longmire, CEO and co-founder of Medable, for a compelling discussion on drug accessibility in cancer care. Together, they explore how decentralized clinical trials and digital tools can help bridge the gap between cutting-edge therapies and the patients who need them most. Dr. Longmire shares how Medable is expanding access to clinical research, particularly in rural and underserved communities, by reimagining how trials are conducted.
The conversation also examines the systemic and financial challenges that often prevent patients from accessing approved cancer...
2025-06-2016 minThe HemOnc PulseThe 'HemOnc Pulse Live' Controversies in Aggressive NHLIn this HemOnc Pulse Live! edition of podcast, Dr. Mehdi Hamadani leads a comprehensive panel discussion on controversies and unanswered questions in the treatment of aggressive non-Hodgkin lymphoma. Dr. Hamadani is joined by Drs. Timothy Fenske, Madiha Iqbal, Urshila Durani, and Mohamed Kharfan-Dabaja.
2025-06-0512h 10The HemOnc PulseInside the War on Myeloid Malignancies: Early Clues & Bold Innovations
In this episode of HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology’s hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting these cancers sooner isn’t just helpful—it’s lifesaving.
2025-05-2320 minThe HemOnc Pulse'The HemOnc Pulse' Live 2025: Controversies in MDSIn this special episode of our podcast, recorded live at HemOnc Pulse Live in Austin, Texas on May 2–3, 2025, leading experts tackle some of the most pressing controversies in the management of myelodysplastic syndromes. Moderated by Naval Daver, MD, this dynamic panel discussion brings together top thought leaders in hematologic malignancies to debate evolving treatment standards, diagnostic challenges, and the integration of emerging therapies in clinical practice.
2025-05-0930 minThe HemOnc PulseRedirected Strategy: Tal and TEC in the Myeloma MixIn this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine. The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and teclistamab (TEC). Drs. Banerjee and Kaur unpack the trial’s rationale, design, and real-world implications for patients with relapsed or refractory disease.
Tune in to hear expert perspectives on unmet needs in late-line myeloma car...
2025-05-0216 min
Hematology PillsCAR-T in Multiple Myeloma: Balancing Innovation, Toxicity, and Access – A Dialogue Between Robin Foà, Filippo Milano and Rahul BanerjeeIn this episode of Hematology Pills, Professor Robin Foà speaks with Dr. Filippo Milano and Dr. Rahul Banerjee about the current role of CAR-T cell therapy in the treatment of multiple myeloma. The discussion touches on key aspects such as therapeutic potential, toxicity management, and the practical issues related to access. Aimed at clinicians and healthcare professionals, the episode provides a clear overview of both opportunities and limitations of this evolving approach.
2025-04-0922 min
i3 Health PodcastAdditional Advances in Relapsed/Refractory Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACPThe fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical.
In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no...
2025-04-0448 min
Oncology Data AdvisorAdditional Advances in Relapsed/Refractory Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACPThe fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical.
In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no...
2025-04-0448 minThe HemOnc PulseDr. Usmani Highlights Myeloma Presentations from SOHO 2024On this episode of "The HemOnc Pulse," Saad Usmani, MD, of the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss notable presentations on multiple myeloma from the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-11-2025 minThe HemOnc PulseCovering MDS Updates at SOHO 2024 With Dr. VenugopalOn this episode of "The HemOnc Pulse," Chadi Nabhan, MD, MBA, FACP, is joined by Sangeetha Venugopal, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami, to highlight data on myelodysplastic syndromes (MDS) presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-11-0125 minThe HemOnc PulseAML News From SOHO 2024 With Dr. DaverOn this episode of "The HemOnc Pulse," Naval Daver, MD, of the MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss news on acute myeloid leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-10-1123 minThe HemOnc PulseDr. Shadman Shares SOHO 2024 Data On CLLOn this episode of "The HemOnc Pulse," Mazyar Shadman, MD, MPH, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to highlight some of the notable presentations on chronic lymphocytic leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-09-2729 min
Couchonomics with ArjunEp 95. Transforming Access And Trading Bonds To A New Era With Rahul BanerjeeIn this episode of Couchonomics with Arjun, we're joined by Rahul Banerjee, Founder & CEO of Bondblox, to explore the future of bond trading. Rahul shares how Bondblox is transforming access to bonds, opening up opportunities for retail investors in a market traditionally controlled by institutions.Arjun and Rahul discuss the rapid growth of the bond market, particularly in Asia, and how technology is playing a key role in bridging the gap between institutional and individual investors. If you're curious about the bond market's impact on your wealth or interested in the latest financial innovations, this conversation is...
2024-09-2451 minThe HemOnc PulseDr. Bose on MPN Highlights From SOHO 2024On this episode of "The HemOnc Pulse," Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss some of the important data on myeloproliferative neoplasms that were presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-09-1726 minThe HemOnc PulsePart Two: The Question of MRD in CLL TherapyIn part two of this episode, Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health, continue to explore the role of measurable residual disease (MRD) in the treatment of patients with chronic lymphocytic leukemia (CLL).
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies.
2024-08-2220 minThe HemOnc PulseDr. Osman on Identifying and Treating High-Risk MDSOn “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and how to approach treatment.
2024-08-0925 minThe HemOnc PulseDr. Rami Komrokji on Trends in Real-World MDS CareOn “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, spoke with Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, about the state of myelodysplastic syndromes (MDS) care. Moffitt Cancer Center is home to a large MDS database, with clinical information on nearly 6,000 patients, a trove of real-world MDS data.
2024-07-2528 minThe HemOnc PulsePart One: The Question of MRD in CLL TherapyPart one of this episode explores questions in measurable residual disease (MRD) and chronic lymphocytic leukemia (CLL) with Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health.
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies.
2024-07-1835 minThe HemOnc Pulse‘The HemOnc Pulse’ Live: Unanswered Questions in T-Cell LymphomaAt the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in T-cell lymphoma management. The panelists were Mehdi Hamadani, MD, a Professor of Internal Medicine at the Medical College of Wisconsin, Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services at Rutgers Cancer Center, and Barbara Pro, MD, a Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.
2024-05-3032 minThe HemOnc Pulse‘The HemOnc Pulse’ Live 2024: Is it Time for New Endpoints in MPN?Recorded at the first annual “HemOnc Pulse” Live meeting, this episode features a panel discussion on unanswered questions in myeloproliferative neoplasms (MPN) with Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center; Ruben Mesa, MD, of the Atrium Health cancer service line; Sanam Loghavi, MD, of the MD Anderson Cancer Center; and Olatoyosi Odenike, MD, of the University of Chicago Medicine.
2024-05-2951 minThe HemOnc PulseUnpacking Bispecifics at ‘The HemOnc Pulse’ Live Meeting“The HemOnc Pulse” was live for the first time in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in a range of hematologic malignancies. As part of the program, Michael Bishop MD, of the University of Chicago, and Aaron Goodman, MD, of the University of California, San Diego, were joined by Rafael Fonseca, MD, of the Mayo Clinic, to hold a panel on bispecific therapies and explore unanswered questions related to them.
2024-05-2446 minThe HemOnc Pulse'The HemOnc Pulse' Live: Unanswered Questions in Treating DLBCLIn this podcast episode covering the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in managing diffuse large B-cell lymphoma. The panelists included Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic; Jane Winter, MD, a Professor of Medicine in the Division of Hematology and Oncology at the Northwestern University Feinberg School of Medicine; and Alan Skarbnik, MD, Director of the Lymphoma and Chronic Lymphocytic Leukemia Program and of Experimental Therapeutics, Malignant Hematology at Novant Health.
2024-05-2332 minThe HemOnc Pulse‘The HemOnc Pulse’ Live 2024: Unanswered Questions in CML TreatmentRecorded at the first “HemOnc Pulse” Live meeting in Chicago, this podcast episode features a panel discussion on unanswered questions in chronic myeloid leukemia (CML) with Elias Jabbour, MD, a Professor of Medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the University of Miami Sylvester Comprehensive Cancer Center; and Sangeetha Venugopal, MD, MS, an Assistant Professor of Medicine at the Sylvester Comprehensive Cancer Center.
2024-05-2128 minThe HemOnc Pulse‘The HemOnc Pulse’ Live: What Are the Unanswered Questions in ALL?Recorded at the first “HemOnc Pulse” annual meeting, this podcast episode features a panel discussion on unanswered questions in acute lymphoblastic leukemia (ALL) with Elias Jabbour, MD, a Professor of Medicine at the University of Texas MD Anderson Cancer Center; Shira Dinner, MD, an Associate Professor of Medicine (Hematology and Oncology) at Northwestern Medicine; Sanam Loghavi, MD, an Associate Professor of Pathology at MD Anderson Cancer Center; and Wendy Stock, MD, Co-Leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center.
2024-05-2132 minThe HemOnc PulseDiscussing the Role of MRD in CLL With Talal Hilal, MDDr. Hilal, of the Mayo Clinic, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss measurable residual disease (MRD) and the debates surrounding its use for response assessment in patients with chronic lymphocytic leukemia (CLL).
2024-05-1621 minThe HemOnc Pulse‘The HemOnc Pulse’ Live 2024: How Is Hodgkin Lymphoma Treated?Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in Hodgkin lymphoma with Andrew Evens, DO, MBA, MSc, Director of the Lymphoma Program and Associate Director of Rutgers Cancer Institute; Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in Division of Hematology at the Mayo Clinic; and Jane Winter, MD, a Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine.
2024-05-1425 minThe HemOnc PulseUnanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in ChicagoRecorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in myelodysplastic syndromes (MDS) with Rami Komrokji, MD, Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center; Sanam Loghavi, MD, an Associate Professor of Pathology at the University of Texas MD Anderson Cancer Center; Jamile Shammo, MD, FACP, FASCP, a Professor at the Northwestern University Feinberg School of Medicine; Sangeetha Venugopal, MD, MS, an Assistant Professor of Medicine at the University of Miami Sylvester Comprehensive Cancer Center; and Amer Zeidan, MBBS, MHS, an Associate Professor of Medicine at Yale University.
2024-05-1331 minThe HemOnc Pulse‘The HemOnc Pulse Live’ in Chicago: Fellows Discuss Choosing a Career Path in Hematology OncologyThis podcast episode features a panel discussion on challenges and opportunities for hematology oncology fellows with Megan Melody, MD, a third-year fellow at Northwestern University; Alexandra Rojek, MD, a second-year fellow at the University of Chicago Medicine Comprehensive Care Center; Seda Tolu, MD, a third-year fellow at the Columbia University Herbert Irving Comprehensive Cancer Center; Zaker Schwabkey, MD, a third-year fellow at Moffit Cancer Center; Himachandana Atluri, MD, a third-year fellow at the University of Texas MD Anderson Cancer Center; and Hannah Goulart, MD, a first-year fellow at MD Anderson Cancer Center.
2024-05-0839 min
i3 Health PodcastAdditional Advances in Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACPDr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for pa...
2024-05-0705 minThe HemOnc Pulse“The HemOnc Pulse” Live 2024 in Chicago: CAR-T Unanswered Questions“The HemOnc Pulse” goes on the road to Chicago May 3-4 with host Chadi Nabhan, MD, MBA, FACP, for the first live meeting.
This podcast episode features a panel discussion on unanswered questions in chimeric antigen receptor (CAR) T-cell therapy with Caron Jacobson, MD, MMSc, Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute; Michael Bishop, MD, FACP, FASCO, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago; Joseph Mikhael, MD, MEd, FRCPC, FACP, a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Research Inst...
2024-05-0538 minThe HemOnc Pulse"The HemOnc Pulse" Live 2024 in Chicago: AML Unanswered Questions"The HemOnc Pulse" goes on the road to Chicago with host Chadi Nabhan, MD, MBA, FACP.
This podcast episode features a panel discussion on unanswered questions in acute myeloid leukemia (AML) with Naval Daver, MD, an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Sanam Loghavi, MD, of the MD Anderson Cancer Center; Rami Komrokji, MD, the Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida; and Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the Sylvester...
2024-05-0434 min
Oncology Data AdvisorAdditional Advances in Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACPDr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for pa...
2024-05-0305 minThe HemOnc PulseWhat are the Controversies Surrounding MRD in Blood Cancers?On this episode of "The HemOnc Pulse," Alan Skarbnik, MD, of Novant Health, and Manni Mohyuddin, MBBS, of the University of Utah, discuss the concept of measurable residual disease (MRD) in hematologic malignancies and highlight the polarized views surrounding MRD.
They also weigh the implications of MRD negativity, how to harmonize the MRD threshold, and how trials are putting MRD technology to the test.
2024-04-2540 minThe HemOnc PulseHMAs Are ‘Cornerstone’ of High-Risk MDS Treatment, Says Jamile Shammo, MDOn this episode of “The HemOnc Pulse,” Dr. Shammo, a Professor of Medicine in Hematology and Oncology at Northwestern Medicine, discusses how to approach treatment for myelodysplastic syndromes (MDS).
Dr. Shammo speaks on everything from low- to high-risk treatment of patients with MDS, including why hypomethylating agents are the cornerstone for treating high-risk patients with MDS.
2024-04-1027 minThe HemOnc PulseKrish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCLDr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.
2024-04-0422 minThe HemOnc PulseAaron Goodman, MD, Tells Us the 'Crux' of Castleman DiseaseIn this episode of "The HemOnc Pulse," Dr. Goodman, an Associate Professor of Medicine at the University of California San Diego, joins Chadi Nabhan, MD, MBA, FACP, to discuss Castleman Disease.
Dr. Goodman explains why the rare disease is often mismanaged, how each subtype is diagnosed and treated, and how it's comparable to hematologic cancers like lymphoma or myeloma.
2024-04-0226 minThe HemOnc PulseIs MRD Negativity the New Benchmark in ALL Treatment Strategies?Elias Jabbour, MD, an Executive Editor of Blood Cancers Today and a Professor of Leukemia at the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss the function of measurable residual disease in treating acute lymphocytic leukemia (ALL) and other progress that has been made in treating patients with Philadelphia chromosome-positive and Philadelphia chromosome-negative ALL.
Dr. Jabbour also provides a brief historical perspective on tyrosine kinase inhibitors (TKIs), explaining how the therapies have improved survival outcomes in Ph+ ALL with or without transplantation.
2024-03-1419 minThe HemOnc PulsePart Two: Drs. Dahiya, Spiegel Return to Discuss 'Black Box' Warning on CAR-T TherapiesSaurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, join The HemOnc Pulse for the second half of a two-part series on reports regarding secondary T-cell malignancies in patients after being treated with a chimeric antigen receptor (CAR) T-cell therapy and updates from the US Food and Drug Administration (FDA) on the issue.
Drs. Dahiya and Spiegel return to the show shortly following the announcement that the FDA sent requests to drug manufacturers on January 9 to update prescription labels with "Black Box" warnings on the six CAR-T therapies used to...
2024-02-2932 minThe HemOnc PulseDr. Coombs Spotlights Recent CHIP UpdatesIn this season's fourth episode of "The HemOnc Pulse," Catherine Coombs, MD, an Associate Professor in the Division of Hematology/Oncology at the University of California, Irvine, School of Medicine, highlights recent studies in clonal hematopoiesis of indeterminate potential (CHIP) presented at the 65th American Society of Hematology Meeting & Exposition.
Dr. Coombs discusses research on reversing the adverse effects of CHIP, particularly its association with atherosclerotic cardiovascular disease, using interventions such as selective nuclear export inhibitors. She also illustrates another study that looks at the prevalence of CHIP in patients undergoing autologous hematopoietic stem cell transplant in l...
2024-02-1529 minThe HemOnc PulseDrs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk
An all-new episode of The HemOnc Pulse with Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, features a discussion on the link between chimeric antigen receptor (CAR)-T cell therapies and secondary T-cell malignancies. The episode follows on the heels of the US Food and Drug Administration's request to drug manufacturers of the six CAR-T therapies to make safety-related labeling changes.
2024-02-0840 min
The HemOnc PulseAditi Shastri, MD: Clinicians Need to ‘Come Together’ on TP53-Mutated MDSThis episode features a conversation between Dr. Shastri, an Assistant Professor of Medicine at the Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York, and The HemOnc Pulse host, Chadi Nabhan; MD; MBA; FACP; on the latest news in myelodysplastic syndromes (MDS), including the final readout from the COMMANDS trial and the clinical implications of TP53-mutated MDS.
2024-01-1823 min
The HemOnc PulseWhat It Takes to Harmonize the World’s Hodgkin Lymphoma DataThe first episode of The HemOnc Pulse of the new year features an in-depth discussion by the leading researchers of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium.
Principal investigators Susan Parsons, MD, MRP; and Andrew Evans, DO, MBA, MSc; are joined by Matthew Maurer, DMSc; to share the story behind harmonizing the world's Hodgkin lymphoma data, and what the effort means for both clinicians and patients.
2024-01-0440 min
The HemOnc PulseDr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma UpdatesSaad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse to chat about the latest research in multiple myeloma from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing in the hematologic oncology space. He also reflects on the Perseus and IsKia trials, which were presented at ASH 2023.
2023-12-1827 min
The HemOnc PulseDr. Venugopal Offers Her Thoughts on the Latest MDS NewsSangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes (MDS), the COMMANDS trial, and if she believes MDS is a distinct disease.
She also highlights the latest research in MDS at the 65th American Society of Hematology Annual Meeting and Exposition.
2023-12-1828 min
The HemOnc PulseJerald Radich, MD: AML Abstracts to Keep an Eye on at ASH 2023In this episode of The HemOnc Pulse, Jerald Radich, MD, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss various abstracts on acute myeloid leukemia (AML) presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. The conversation centered around menin inhibitors for the treatment of AML, the effect of measurable residual disease-positivity on transplantation outcomes, and whether age plays a role in transplantation.
2023-12-1736 min
The HemOnc PulseInside the FDA ODAC ’Yes’ Vote to PolivyIn this episode of The HemOnc Pulse, Grzegorz Nowakowski MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, recounts his experience serving on the FDA Oncologic Drugs Advisory Committee that reviewed and evaluated data from the POLARIX study and polatuzumab vedotin-piiq (Polivy)for patients with previously untreated LBCL.
2023-11-3031 min
The HemOnc PulseKami Maddocks, MD, on the Shocking Ibrutinib WithdrawalIn this episode of The HemOnc Pulse, Dr. Maddocks, Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University, charts the treatment evolution of mantle cell lymphoma (MCL) from frontline therapy to future directions. She also explains her initial shock, and subsequent bittersweet reaction to the withdrawal of ibrutinib.
2023-11-1631 min
Oncology Data AdvisorVenetoclax for Multiple Myeloma in the Post-CANOVA Era: Rahul Banerjee, MD, FACP, and Andrew Yee, MDAt the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the CANOVA study of venetoclax for patients with relapsed/refractory multiple myeloma. After returning from the meeting, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and Oncology Data Advisor Editorial Board Member, and Dr. Andrew Yee, Clinical Director for Multiple Myeloma at Massachusetts General Hospital, sat down to reflect on the surprising results of the trial and its implications for the current and future treatment of patients with t(11;14) multiple myeloma.
2023-11-1520 minOncology Data AdvisorUpdates on Bispecific Antibodies in Multiple Myeloma From IMS 2023: Rahul Banerjee and Shonali MidhaAt this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.
2023-11-0718 min
The HemOnc PulseJorge Cortes, MD, on Why Balance Is Key in CML TherapyDr. Cortes, who serves as Director of the Georgia Cancer Center at Augusta University, joins host Chadi Nabhan, MD, MBA, FACP, to chat about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Dr. Cortes discussed the evolution of tyrosine kinase inhibitors (TKIs) and the multiple generations of TKIs that are now available. Second-generation TKIs can lead to earlier and deeper responses than first-generation TKIs, he said, noting that this means patients receiving second-generation TKIs are more likely to be able to discontinue treatment.
“If I was diagnosed with CML, I would take a...
2023-11-0223 minOncology Data AdvisorTwice Weekly, Biweekly, Somewhere in Between? Dosing in Myeloma: Rahul Banerjee and Gurbakhash KaurIn honor of Blood Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Dr. Rahul Banerjee sat down with Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas Southwestern Medical Center, to discuss updates and the advantages and disadvantages of different dosing schedules for treating multiple myeloma.
2023-10-2317 min
The HemOnc PulseWhat Are the Top Questions in ALL?Elias Jabbour, MD, of the University of MD Anderson Cancer Center stops by The HemOnc Pulse for a live show at the Eleventh Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
In this episode, Dr. Jabbour, who is also an Associate Editor of Blood Cancers Today, the home of The HemOnc Pulse, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
2023-10-1924 min
The HemOnc PulseThe ABCs of MM Treatment According to Rafael Fonseca, MDDr. Fonseca offers his thoughts on the future of multiple myeloma (MM) treatment, the ongoing debate between chimeric antigen receptor (CAR)-T therapies and bispecifics, and the latest treatment news on bispecifics, including elranatamab, which had yet to be approved at the time of this recording.
The conversation also covers the role of measurable residual disease (MRD), the potential for bispecific therapies to democratize access to advanced treatments, and the intriguing prospect of CAR-T cells potentially replacing hematopoietic stem cell transplants in the first relapse—a scenario reminiscent of lymphoma care.
"I don't think it's far-fetched to think that there's go...
2023-10-0529 min
The HemOnc PulseThe Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL TreatmentOn this episode of The HemOnc Pulse, guest Jonathan Friedberg, MD, MMSc, a hematologic oncologist at the University of Rochester Medicine – Wilmot Cancer Institute, chats with host Dr. Chadi Nabhan on the subtle but important shift in the treatment landscape of diffuse large B-cell lymphoma (DLBCL)in the post-POLARIX trial era.
The POLARIX trial, which was designed to improve upon the standard R-CHOP regimen for DLBCL treatment, investigated the potential of polatuzumab vedotin. The phase III trial ultimately resulted in the US Food and Drug Administration approving the treatment in previously untreated DLBCL, not otherwise specified, or high-grade B-cell lymphoma. Th...
2023-09-1433 min
The HemOnc PulseDr. Garcia-Manero on the Data Behind the Luspatercept ApprovalGuillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, live at the Eleventh Annual Meeting of the Society of Hematologic Oncology to discuss the phase III COMMANDS trial, the recent approval of luspatercept, and other developments in myelodysplastic syndromes (MDS) treatment and research.
Dr. Garcia-Manero spoke about the design of the phase III COMMANDS trial, which evaluated luspatercept versus epoetin alfa for the treatment of anemia in patients with lower-risk MDS who required red blood cell (RBC) transfusions but had not previously received an erythropoiesis-stimulating agent.
“The study is very interesting in...
2023-09-1320 min
The HemOnc PulseMazyar Shadman, MD, MPH, Reports the Latest BTKi News in CLLDr. Shadman of the Fred Hutchinson Cancer Center in Seattle rounds up the latest news in chronic lymphocytic leukemia (CLL) from the summer conferences, including updates on novel Bruton tyrosine kinase inhibitor (BTKi) therapies in CLL.
2023-08-2426 min
The HemOnc PulseBhavana Bhatnagar, MD, on the Molecular Revolution in AMLIn this episode of The HemOnc Pulse, Dr. Bhatnagar, an Associate Professor of Medicine at the West Virigina University Cancer Institute, reflects on how the molecular characterization of acute myeloid leukemia (AML) has evolved. She joins host Chadi Nabhan, MD, MBA, FACP, to discuss how this growing base of knowledge has impacted diagnosis, treatment, and classification.
“The most significant changes have come about as a result of improvements and refinements in the molecular characterization of AML,” Dr. Bhatnagar said.
Some of these changes include major updates in the World Health Organization and European LeukemiaNet systems.
The episode also highlights Dr. Bhat...
2023-08-1025 min
The HemOnc PulseDo Venetoclax Combinations Trump Chemotherapy in Frontline CLL Treatment?Is there a venetoclax combination that reigns supreme in chronic lymphocytic leukemia (CLL)? Is venetoclax-based therapy the way to go in treating frontline CLL? Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, shares his thoughts on these questions and recent data published in the New England Journal of Medicine.
2023-07-2724 min
The HemOnc PulseWhy Grzegorz Nowakowski, MD, Says There’s a ‘Revolution’ in LBCL TherapyDr. Nowakowski, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, talks about the revolution in treatment options in diffuse large B-cell lymphoma(DLBCL).
"The last couple of years, we've seen quite a revolution in the treatment of DLBCL," he said. "We have multiple approved therapies now, and more coming, so it's really a very rapidly changing field."
He also discusses the five-year follow-up data from the L-MIND study, which evaluated tafasitamab in combination with lenalidomide.
2023-07-1325 min
The HemOnc PulseAn Expert’s Look into the World of Rare Blood CancersNaveen Pemmaraju, MD, Associate Professor at the University of Texas MD Anderson Cancer Center, talks about the rare, ultrarare, and forgotten blood cancers, including his lifelong work in blastic plasmacytoid dendritic cell neoplasm (BPDCN), in this episode of The HemOnc Pulse.
2023-06-2925 min
The HemOnc PulseThe Logistics of CAR-T in Hematologic MalignanciesNavneet Majhail, MD, MS, the Physician in Chief at Sarah Cannon in Nashville, Tennessee, delves into the intricacies of chimeric antigen receptor (CAR) T-cell therapy, discussing the logistics and challenges involved with these therapies.
Dr. Majhail explores strategies to improve access to CAR-T therapy and he discusses the role of CAR-T amidst the availability of bispecific antibodies as treatments for blood cancers.
2023-06-1525 min
The HemOnc PulseAbi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost EffectiveDrs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.
2023-05-1832 min
The HemOnc PulseSagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MMBlood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.
2023-05-0422 min
The HemOnc PulseAlan Skarbnik, MD, Gives the Lowdown on Treating Patients with Follicular LymphomaAlan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma, the nuances involved in those decisions, and why bispecifics are here to stay, with host Chadi Nabhan, MD, MBA, FACP.
2023-04-2032 min
FUMO: Future Of Money Podcast58. Blockchain & Bonds: Reinventing Finance with Digital Ledger Technology | (with Rahul Banerjee, Founder & CEO Bondevalue)Are you curious about the potential impact of blockchain technology in the bond market?
Our next podcast episode features an interview with Rahul Banerjee, Founder & CEO of Bondevalue, who will discuss the use of digital ledger technology in finance, particularly in the bond market. He highlights how blockchain technology can help create a more efficient and trustworthy bond market by removing intermediaries like banks or financial institutions. Rahul also shares that he created an app called Bondevalue, which has since been rebranded as Bond Blocks, to reinvent the bond market using blockchain technology.
Don’t mi...
2023-04-1048 min
The HemOnc PulseAmer Zeidan, MBBS, MHS, on the Evolution of AML Classification, TreatmentIn this episode of The HemOnc Pulse, Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates, the practical implications of testing for genetic alterations, and how patient characteristics inform his approach to treating AML, with host Chadi Nabhan, MD, MBA, FACP.
2023-04-0626 min
The HemOnc PulseWhat Is the Cost-Effectiveness of Pola-R-CHP in DLBCL?Swetha Kambhampati, MD, and Nikhil Thiruvengadam, MD, discuss the implications of their study investigating the cost-effectiveness of pola-R-CHP in previously untreated DLBCL.
2023-03-2327 min
The HemOnc PulseGraham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin LymphomaIn the latest episode of The HemOnc Pulse, Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, a lymphoma specialist at Oxford Cancer and Haematology Centre, discusses the findings from the HoLISTIC Consortium, and what he thinks about checkpoint inhibitors upfront in the treatment of Hodgkin lymphoma.
2023-03-0935 min
The HemOnc PulseWhat Keeps Michael Bishop, MD, Up at Night When it Comes to CAR-T?What is it about chimeric antigen receptor (CAR) T-cell therapies in hematologic oncology that keeps Michael Bishop, MD, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago, awake at night? In the latest episode of the podcast, Dr. Bishop discusses the matter and speaks about research that is identifying why CAR T-cell therapy doesn't always work.
2023-02-2336 min
The HemOnc PulseLaurie H. Sehn, MD, MPH, on the Game-Changing Bispecifics in Follicular LymphomaIn the latest episode of The HemOnc Pulse, Laurie H. Sehn, MD, MPH, Chair of the Lymphoma Tumour Group at the BC Cancer Centre for Lymphoid Cancer, talks with host Chadi Nabhan, MD, MBA, FACP, about which bispecific antibodies will change the game in follicular lymphoma treatment. Dr. Sehn also explains why the TRIANGLE study is anticipated to be practice-changing and how it may make upfront transplant obsolete in MCL.
2023-02-0937 min
The HemOnc PulseSanam Loghavi, MD, Tells Us Why 2022 was a Major Year for MDSSanam Loghavi, MD, stops by The HemOnc Pulse and chats with host Chadi Nabhan, MD, MBA, FACP, about why she thinks 2022 was a major year for MDS in this latest episode of the podcast. With the unveiling of the two new MDS classification systems in the past year, Dr. Loghavi breaks down the classification models and what it means for the specialty.
2023-01-2639 min
The HemOnc PulseElizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be IgnoredIn the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Brem discusses which chronic lymphocytic leukemia (CLL) abstracts from ASH 2022 cannot be ignored, the latest news in Richter’s transformation, and why she is moving away from ibrutinib in her own clinical practice.
2023-01-1236 min
The HemOnc PulseRuben Mesa, MD, Discusses MPN Updates at ASH 2022 and the Evolution of the DiseaseRuben Mesa, MD, President and Executive Director of the Atrium Health cancer service line (formerly the Executive Director of Mays Cancer Center), discusses his long career in myeloproliferative neoplasms (MPNs), the evolution of the disease, and what abstracts caught his attention at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.
2022-12-2930 min
The HemOnc PulseDrs. Hagop Kantarjian and Elias Jabbour Discuss Important AML, ALL Updates From ASH 2022In the inaugural episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Hagop Kantarjian, MD, and Elias Jabbour, MD, both of the Department of Leukemia at the University of Texas MD Anderson Cancer Center. The trio cover high-impact studies, novel treatment strategies, and controversial standard-of-care approaches for AML as well as ALL that were presented at the 2022 American Society of Hematology Annual Meeting & Exposition.
2022-12-1444 min
Oncology Data AdvisorUnderstanding Clonal Hematopoiesis With Rahul Banerjee, Jeremy Meier, and Samuel RubinsteinDr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.
2022-11-1425 min
Oncology Data AdvisorBlood Cancer Awareness Month: Exploring Patient-Reported Outcomes: Rahul Banerjee and Ajay MajorRecently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role of patient-reported outcomes (PROs) in lymphoma and myeloma, including how to interpret them and how to include them when designing research.
2022-10-0731 minOncology Data AdvisorConsidering VTE Risk Factors and Prophylaxis in Myeloma: Rajshekhar Chakraborty and Rahul BanerjeeIn this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Rajshekhar Chakraborty about risk factors for the development of venous thromboembolism (VTE) in patients with multiple myeloma and the considerations for thromboprophylaxis during their treatment.
2022-04-1119 minOncology Data AdvisorCan Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul BanerjeeIn honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma.
2022-04-0623 minOncology Data AdvisorAdvocating for Patients in Multiple Myeloma Clinical Trials: Manni Mohyuddin and Rahul BanerjeeIn this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myeloma.
2022-03-2424 minOncology Data AdvisorCan Digital Life Coaching Improve Quality of Life in Transplant? Rahul Banerjee and Kelly BrassilDr. Rahul Banerjee and Dr. Kelly Brassil discuss the design of an ongoing phase 2 trial investigating digital life coaching and its implications for improving the quality of life of patients undergoing ASCT for multiple myeloma.
2022-02-1727 min
Plenary Session - inactive due to federal service4.06 CAR-T, Oncology RCTs, Social Media, Myeloma, and Career Decisions with Dr. Rahul BanerjeeWe sat down in person with Dr. Rahul Banerjee, a BMT/CAR-T fellow at UCSF, to talk about all manner of topics including CAR-T, randomized trials in oncology (and, specifically, Dr. Banerjee's two recent papers out now), social media, treating Multiple Myeloma, and how people make career decisions.
What Oncologists Can Learn From COVID-19: doi.org/10.1038/s41571-020-00448-y
Are Observational, Real-World Studies Suitable: doi.org/10.1001/jamanetworkopen.2020.12119
Back us on Patreon! www.patreon.com/plenarysession
Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
2021-07-081h 31Plenary Session - inactive due to federal service4.06 CAR-T, Oncology RCTs, Social Media, Myeloma, and Career Decisions with Dr. Rahul BanerjeeWe sat down in person with Dr. Rahul Banerjee, a BMT/CAR-T fellow at UCSF, to talk about all manner of topics including CAR-T, randomized trials in oncology (and, specifically, Dr. Banerjee's two recent papers out now), social media, treating Multiple Myeloma, and how people make career decisions.
What Oncologists Can Learn From COVID-19: doi.org/10.1038/s41571-020-00448-y
Are Observational, Real-World Studies Suitable: doi.org/10.1001/jamanetworkopen.2020.12119
Back us on Patreon! www.patreon.com/plenarysession
Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew
2021-07-081h 31
Where Dreams Come FromRahul Banerjee (English)Trained as an engineer at the Indian Institutes of Technology or IIT, my guest Rahul Banerjee gave up the securities of an Indian middle class life to serve his country. He threw his lot behind the indigenous Bhil tribal folk in central India. Along the way, he has completed a PhD, become an Ashoka Fellow and completed numerous research projects for organizations internationally. But the central focus, as Banerjee explains, has been a lifelong process of unlearning and then organizing to secure constitutional rights for the poorest of the poor in India. This conversation is a snapshot of that...
2021-05-1924 min